Aethlon Medical Releases Smallpox Related Data.

SAN DIEGO -- Aethlon Medical, Inc. (OTCBB:AEMD) announced today its scientists have completed initial non-clinical human blood studies which indicate that the Hemopurifier(TM) treatment technology is effective in capturing smallpox related viruses from human blood. The studies documented that the Hemopurifier was able to capture 85% of Vaccinia from human blood in one hour and in excess of 95% during an overnight treatment study. Vaccinia is a "pox"-type virus closely related to smallpox. Related studies also indicated that the Hemopurifier was effective in removing other smallpox related viruses, including cowpox and mousepox.

"Taken together, these studies strongly indicate that the Hemopurifier(TM) will be effective in removing circulating smallpox virus from the blood of infected patients, even when the virus has been engineered to be resistant to drugs and vaccines," stated Richard H. Tullis, Ph.D., Aethlon's Chief Scientific Officer.

Aethlon's clinical goal is to develop the Hemopurifier as a countermeasure against smallpox and other viruses and toxins that are referenced in the U.S. government's stated plan to acquire emergency stockpiles of treatments against candidate biological weapons. Project BioShield, which was signed into law on July 21, 2004, authorizes $5.6 billion over 10 years to purchase and deploy new countermeasures against Smallpox, Anthrax, Ebola, Marburg, Plague, and other potential bioterror agents. Under Project BioShield, clinical efficacy for these bioweapons is established in animal models rather than in large-scale human trials. Aethlon believes that the Hemopurifier can serve as the first line of defense in treating drug and vaccine resistant biological weapons.

About Aethlon Medical

Aethlon Medical is pioneering the development of viral filtration devices to treat HIV/AIDS, Hepatitis-C (HCV), and pathogens that are mass casualty biological warfare candidates. Each treatment application employs the use of a proprietary technology known as the Hemopurifier(TM), which is designed to rapidly reduce the presence of infectious disease and toxins in the body. The Hemopurifier converges the established scientific principals of affinity chromatography and hemodialysis as a means to augment the immune response of clearing viruses and toxins from the blood before cell and organ infection can occur. More information on Aethlon Medical and the Hemopruifier technology is available at www.aethlonmedical.com.

Certain of the statements herein may be forward-looking and involve risks and uncertainties. Such forward-looking statements involve assumptions, known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Aethlon Medical, Inc. to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such potential risks and uncertainties include, without limitation, the Company's ability to raise capital when needed, the Company's ability to complete the development of its planned products, the ability of the Company to obtain FDA and other regulatory approvals permitting the sale of its products, the Company's ability to manufacture its products and provide its services, the impact of government regulations, patent protection on the Company's proprietary technology, product liability exposure, uncertainty of market acceptance, competition, technological change, and other risk factors. In such instances, actual results could differ materially as a result of a variety of factors, including the risks associated with the effect of changing economic conditions and other risk factors detailed in the Company's Securities and Exchange Commission filings.